1. Galecto approved stock options for a new employee. 2. 312,535 shares at an exercise price of $32.00. 3. Options vest over several months, contingent on employment. 4. Company focusing on hematological cancers with innovative therapies. 5. IND filing for lead asset expected in mid-2026.
FAQ
Why Bullish?
The grant aims to attract talent, indicating growth potential. Historically, similar grants have yielded positive stock responses in biotech.
How important is it?
The talent acquisition reflects positively on the company’s strategy, but is not a direct revenue driver.
Why Long Term?
The IND filing for DMR-001 signals significant future developments. Long-term investor sentiment may improve as pipeline advances.
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the "Company" or "Galecto") (NASDAQ:GLTO) today announced that the Company's Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the Company's common stock to one new employee (the "Inducement Grant") on December 15, 2025 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company's 2022 Inducement Plan, as amended from time to time. The Inducement Grant was granted as an inducement material to this individual entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share equal to $32.00 and will vest (i) with respect to 25% on the first anniversary of the Grant Date and (ii) thereafter, with respect to an additional 1/48th on each monthly anniversary of the Grant Date following the first anniversary of the Grant Date, subject to the employee's continued employment with the Company through the applicable vesting dates.
About Galecto
Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto's pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. The Company expects to submit an IND or equivalent filing for lead asset, DMR-001, a potentially best-in-class, subcutaneously administered monoclonal antibody targeting mutCALR, in mid-2026. Galecto's pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of AML. For regular updates about Galecto, visit www.galecto.com.
Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com
Investor Contact:
Sandya von der Weid
LifeSci
svonderweid@lifesciadvisors.com
